Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
Do you consider immunosuppression in a patient with cocaine-induced midline lesions who is ANCA positive, but has no other evidence of vasculitis?
Related Questions
Would you give IVIG for Rituximab induced immunodeficiency in patients with reduced kidney function from renal GPA?
How would you interpret the presence of both high titer anti-PR3 and anti-MPO antibodies in a pANCA positive patient with evidence of small vessel vasculitis?
How would you approach management of a patient with classic GCA symptoms, elevated ESR and improvement with steroids, but negative temporal artery biopsy and CTA imaging without evidence of vasculitis?
Do you send anti-human neutrophil elastase antibodies when you suspect levamisole-induced ANCA vasculitis?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
How soon after starting treatment would you repeat imaging in patients with Takayasu to monitor response and ensure you have the correct diagnosis?
Would you consider tocilizumab for treatment of GCA in patients with underlying CLL (not requiring therapy)?
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
How would you manage a patient on tocilizumab for recently diagnosed severe GCA who developed a bowel obstruction several weeks after the first dose of Tocilizumab?
